Artificial cells for oral delivery of live bacterial cells for therapy - Artificial Cells, Cell Engineering and Therapy - page 191

Table 8.1 Continued

Targeted Bacterial cells Proposed mode of action References

therapy

Lower LDL- L. plantarum Bacteria may bind or incorporate 99, 101,

cholesterol 299V cholesterol directly into the cell 103±105,

and L. acidophilus membrane. Bile salt hydrolase (BSH) 108±110,

triglycerides L. bulgaricus enzyme deconjugates intraluminal 184

L. reuteri bile acids making them less likely to

be reabsorbed into the
enterohepatic circulation (ECH),
causing de novo synthesis of bile
acids from blood serum cholesterol.

Irritable L. plantarum Restoration of normal intestinal 91, 93±96

bowel 299V microflora; shorter colonic transit

syndrome L. paracasei F19 times. Increased tolerance to certain

B. breve foods.

E. coli Nissle
1917
B. cereus Toyos
B. subtilis
P. freudenreichii
JS

Chronic L. acidophilus Reduction in blood levels of uremic 185±187

kidney failure Lactic acid toxins produced in the intestine as

bacteria bacterial putrefactive metabolites.

Inhibition of bacterial proliferation;
correction of the intestinal microflora.

Kidney stones L. acidophilus Reduction in urinary excretion of 188, 189

L. plantarum oxalate; oxalate-degrading enzymes
L. brevis break down the unwanted oxalate;
S. thermophilus can be used to prevent the
B. infantis subsequent evolution of kidney

O. faecalis stones.

Allergy L. rhamnosus Counterbalancing the skewed T H 2 54±56

GG immune phenotype in the gut;
L. paracasei 33 reduced colonization of bacterial
E. coli Nissle

pathogens; boost in the systemic

1917 immune response.

LGG; B. lactis
Bb12;
Combination
of L. rhamnosus
19070-2 and
L. reuteri DSM
122460